Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 145,033 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorder Clear all
Terminated No phase listed Observational

Trial Comparing Ketorolac Tromethamine 0.4% & Prednisolone Acetate 1% in Reducing Post-SLT Anterior Chamber Flare & Cells

NCT00410267
View directory record Official record
Conditions
Postoperative Complications, Inflammation, Glaucoma, Open-Angle
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 95 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 21, 2026, 5:50 PM EDT
Withdrawn Phase 4 Interventional

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

NCT03580967
View directory record Official record
Conditions
Type2 Diabetes, Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Todd Doyle
Other
Eligibility
40 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy of Intravenous Levetiracetam in Neonatal Seizures

NCT01720667
View directory record Official record
Conditions
Neonatal Seizures
Interventions
Intravenous levetiracetam, Intravenous phenobarbital
Drug
Lead sponsor
Richard H. Haas
Other
Eligibility
15 Minutes to 14 Days
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 21, 2026, 5:50 PM EDT
Recruiting No phase listed Observational

Explanted Lung Tissues With Pulmonary Fibrosis

NCT00515567
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Phase 2 Interventional Results available

Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides

NCT01073267
View directory record Official record
Conditions
Lymphoma
Interventions
TSEBT
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

NCT05486065
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
101
States / cities
Birmingham, Alabama • Banning, California • Chula Vista, California + 83 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 21, 2026, 5:50 PM EDT
Recruiting Phase 3 Interventional

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800
View directory record Official record
Conditions
Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
Interventions
PF-08634404, Bevacizumab, Chemotherapy
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
254
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 173 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria

NCT05884307
View directory record Official record
Conditions
Gender Dysphoria
Interventions
Trans Care Web App
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 5:50 PM EDT
Terminated Phase 2 Interventional Results available

Thiamine as a Metabolic Resuscitator After Cardiac Arrest

NCT03450707
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Thiamine 500 mg IV, Placebo
Drug · Other
Lead sponsor
Michael Donnino
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Phase 4 Interventional Results available

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

NCT00087607
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, Peginterferon alfa-2b (PEG-Intron), Peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 21, 2026, 5:50 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

NCT07154511
View directory record Official record
Conditions
Parkinson Disease, Parkinson Disease Dementia
Interventions
Tributyrin, Placebo
Drug
Lead sponsor
Prabesh Kanel
Other
Eligibility
45 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 5:50 PM EDT
Terminated Phase 2 Interventional

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

NCT00211471
View directory record Official record
Conditions
Severe Diabetic Retinopathy, Central Retinal Vein Occlusion, Chronic Inflammation, Infectious Diseases
Interventions
anecortave acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Not applicable Interventional

Effects of Music Listening on Pain and Patient Satisfaction Within First 48 Hours After Knee Replacment Surgery

NCT02039271
View directory record Official record
Conditions
Adjunctive Music Therapy in Total Knee Replacement
Interventions
Music therapy
Other
Lead sponsor
Loma Linda University
Other
Eligibility
50 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 21, 2026, 5:50 PM EDT
Active, not recruiting No phase listed Observational

Use of Intrapyloric Botulinum Injections in Children

NCT04250844
View directory record Official record
Conditions
Vomiting, Feeding Disorders, Gastroparesis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 18 Years
Enrollment
100 participants
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 21, 2026, 5:50 PM EDT
Recruiting Phase 1 Interventional

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

NCT06287944
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants

NCT06106334
View directory record Official record
Conditions
Obesity, Healthy Volunteers
Interventions
S309309, Itraconazole
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 21, 2026, 5:50 PM EDT
Terminated Phase 2 Interventional Results available

Aflibercept for Relapsed Multiple Myeloma

NCT00437034
View directory record Official record
Conditions
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
aflibercept
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Manhasset, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 21, 2026, 5:50 PM EDT
Recruiting Phase 4 Interventional

Establishing Mobile Transcranial Magnetic Stimulation

NCT06748209
View directory record Official record
Conditions
Treatment Resistant Major Depression
Interventions
Left prefrontal Transcranial Magnetic Stimulation (TMS), FDA cleared TMS for treating depression
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
22 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Phase 1 Interventional

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

NCT02293109
View directory record Official record
Conditions
Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
carfilzomib, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, cytarabine, leucovorin calcium, methylprednisolone, rituximab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Mehrdad Abedi, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"

NCT03740009
View directory record Official record
Conditions
Perimenopausal Disorder, Depression
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 21, 2026, 5:50 PM EDT
Recruiting Not applicable Interventional

Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes

NCT06503809
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Ketogenic Diet, Standard Diet
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 21, 2026, 5:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

NCT04418999
View directory record Official record
Conditions
Keratoconus, Dry Eye, Allergy
Interventions
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Drug
Lead sponsor
Illinois College of Optometry
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 21, 2026, 5:50 PM EDT
Withdrawn Phase 1 Interventional

A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

NCT00487799
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Ularitide
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Oct 21, 2026, 5:50 PM EDT